Clinical Trial Update: Immunogenicity and Safety of Human Papillomavirus (HPV)-16/18 Vaccine in Healthy Females [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating the immunogenicity and safety of an HPV-16/18 vaccine in healthy females.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer Risk
• Human Papillomavirus Infection

Drugs mentioned

• HPV-16/18 vaccine (Cervarix)

Snippet

Sponsor: Shanghai Zerun Biotechnology Co.,Ltd | Conditions: Human Papillomavirus | Phase 2 | Status: COMPLETED